Related Pages for DRREDDY
DRREDDY
Dr. Reddy S LaboratoriesNo results found.
DRREDDY
1336.7
Related News - DRREDDY
Dr. Reddy's Laboratories: Co launches its generic semaglutide injection in Canada
16 May 2026 07:04 AM
Dr. Reddy's Laboratories: Co launches its generic semaglutide injection in Canada
Dr Reddy's Labs: Anticipates Continued Double-Digit Growth For Its Core Business Next Year, With Gross Margins Projected To Exceed 50% In FY '27 Due To Cost Savings, Increased Efficiency, And New Product Introductions Like Semaglutide.
13 May 2026 09:04 AM
Dr Reddy's Labs: Anticipates Continued Double-Digit Growth For Its Core Business Next Year, With Gross Margins Projected To Exceed 50% In FY '27 Due To Cost Savings, Increased Efficiency, And New Product Introductions Like Semaglutide.
Dr Reddy's Labs: Expects SG&A Expenses To Stay Around FY '26 Levels, R&D Spending Projected At 7% To 8% Of Adjusted Revenues, With Effective Tax Rate Anticipated At 24% To 25% For FY '27. North America Anticipates Double-Digit Growth Excluding Lenalidomide, With Additional Sales From Semaglutide.
13 May 2026 09:04 AM
Dr Reddy's Labs: Expects SG&A Expenses To Stay Around FY '26 Levels, R&D Spending Projected At 7% To 8% Of Adjusted Revenues, With Effective Tax Rate Anticipated At 24% To 25% For FY '27. North America Anticipates Double-Digit Growth Excluding Lenalidomide, With Additional Sales From Semaglutide.
Dr. Reddy's Labs: Plans To Keep EBITDA Margin Around 20% Without Semaglutide, Expecting It To Rise To About 25% With Semaglutide Sales. Sales Could Reach 6-7 Million Units By End Of 2026 And Target 10-11 Million Pens Per Quarter For FY 2027, Possibly Extending Into FY 2028 Due To Delays.
13 May 2026 09:04 AM
Dr. Reddy's Labs: Plans To Keep EBITDA Margin Around 20% Without Semaglutide, Expecting It To Rise To About 25% With Semaglutide Sales. Sales Could Reach 6-7 Million Units By End Of 2026 And Target 10-11 Million Pens Per Quarter For FY 2027, Possibly Extending Into FY 2028 Due To Delays.
Dr Reddy's Labs: Anticipates Semaglutide Pricing Around $30+ Per Unit, With A Minimum Price Of $25, And Higher Prices Possible In Some Markets. Annual Biosimilar Sales Are Expected To Reach Between $0.5 Billion And $700 Million By FY '29, Depending On Abatacept's Performance. Projected Capital Expenditure For Next Year (FY '27) Is Approximately INR 2,000 Crores.
13 May 2026 09:04 AM
Dr Reddy's Labs: Anticipates Semaglutide Pricing Around $30+ Per Unit, With A Minimum Price Of $25, And Higher Prices Possible In Some Markets. Annual Biosimilar Sales Are Expected To Reach Between $0.5 Billion And $700 Million By FY '29, Depending On Abatacept's Performance. Projected Capital Expenditure For Next Year (FY '27) Is Approximately INR 2,000 Crores.
Dr. Reddy's Lab: Plans To Launch Generic Version Of Oral Semaglutide Soon. - ET
13 May 2026 08:50 AM
Dr. Reddy's Lab: Plans To Launch Generic Version Of Oral Semaglutide Soon. - ET
Dr. Reddy’s: Nomura maintains a Buy on Dr. Reddy’s with a Target Price of ₹1600, noting Q4 sales were slightly ahead of estimates despite EBITDA being marginally below, while management expects sustained double-digit revenue growth across markets, improving gross margins to 50–55%, and EBITDA margins around 20% excluding Semaglutide contributions.
13 May 2026 08:41 AM
Dr. Reddy’s: Nomura maintains a Buy on Dr. Reddy’s with a Target Price of ₹1600, noting Q4 sales were slightly ahead of estimates despite EBITDA being marginally below, while management expects sustained double-digit revenue growth across markets, improving gross margins to 50–55%, and EBITDA margins around 20% excluding Semaglutide contributions.
Dr. Reddy’s: Morgan Stanley maintains an Equal-weight on Dr. Reddy’s with a Target Price of ₹1215, citing adjusted revenue and EBITDA missing estimates by 2% and 13% respectively, while noting a slight delay in Semaglutide ramp-up pending Brazil approval, though the company expects 6–7 million pen sales in CY2026 and plans to scale capacity beyond 40 million by FY28.
13 May 2026 08:41 AM
Dr. Reddy’s: Morgan Stanley maintains an Equal-weight on Dr. Reddy’s with a Target Price of ₹1215, citing adjusted revenue and EBITDA missing estimates by 2% and 13% respectively, while noting a slight delay in Semaglutide ramp-up pending Brazil approval, though the company expects 6–7 million pen sales in CY2026 and plans to scale capacity beyond 40 million by FY28.
Dr. Reddy’s: Jefferies maintains an Underperform on Dr. Reddy’s with a Target Price of ₹1040, citing a weak March quarter with material misses even after adjusting for one-offs, margin pressure from weak US performance and high SG&A costs despite growth in India, Russia and Europe, while management’s FY27 double-digit revenue growth guidance excluding gRevlimid remains in line, though slower Semaglutide uptake in Canada and delays in Abatacept launches pose downside risks.
13 May 2026 08:41 AM
Dr. Reddy’s: Jefferies maintains an Underperform on Dr. Reddy’s with a Target Price of ₹1040, citing a weak March quarter with material misses even after adjusting for one-offs, margin pressure from weak US performance and high SG&A costs despite growth in India, Russia and Europe, while management’s FY27 double-digit revenue growth guidance excluding gRevlimid remains in line, though slower Semaglutide uptake in Canada and delays in Abatacept launches pose downside risks.
Dr. Reddy: Labs Plans To Introduce Oral And Injectable Semaglutide In All Markets In The Future.
12 May 2026 06:28 PM
Dr. Reddy: Labs Plans To Introduce Oral And Injectable Semaglutide In All Markets In The Future.
Dr Reddy: Labs Plans To Launch Semaglutide In Canada And India Soon This Month.
12 May 2026 05:59 PM
Dr Reddy: Labs Plans To Launch Semaglutide In Canada And India Soon This Month.
DR REDDY'S LABS: Q4 CONS NET PROFIT 2.21B RUPEES VS 15.94B (YOY) || Q4 REVENUE 75.46B RUPEES VS 85.3B (YOY)
12 May 2026 04:47 PM
DR REDDY'S LABS: Q4 CONS NET PROFIT 2.21B RUPEES VS 15.94B (YOY) || Q4 REVENUE 75.46B RUPEES VS 85.3B (YOY)
DR REDDY'S LABS: Q4 EBITDA 3.8B RUPEES VS 19.98B (YOY) || Q4 EBITDA MARGIN 5.07% VS 23.43% (YOY)
12 May 2026 04:48 PM
DR REDDY'S LABS: Q4 EBITDA 3.8B RUPEES VS 19.98B (YOY) || Q4 EBITDA MARGIN 5.07% VS 23.43% (YOY)
DR REDDY'S LABS: BOARD RECOMMENDS FINAL DIVIDEND OF ₹8 PER SHARE
12 May 2026 04:48 PM
DR REDDY'S LABS: BOARD RECOMMENDS FINAL DIVIDEND OF ₹8 PER SHARE
Dr Reddy’s Labs: Citi maintains 'Sell' on DrReddy with Price Target of Rs 990
08 Jan 2026 07:48 AM
Dr Reddy’s Labs: Citi maintains 'Sell' on DrReddy with Price Target of Rs 990
